Machina Capital S.A.S. Buys 13,426 Shares of Hologic, Inc. $HOLX

Machina Capital S.A.S. lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 264.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,494 shares of the medical equipment provider’s stock after purchasing an additional 13,426 shares during the quarter. Machina Capital S.A.S.’s holdings in Hologic were worth $1,248,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its holdings in shares of Hologic by 294.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after acquiring an additional 8,227,318 shares in the last quarter. Invesco Ltd. increased its position in Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the last quarter. Norges Bank purchased a new stake in Hologic during the second quarter valued at $180,055,000. Allspring Global Investments Holdings LLC lifted its position in Hologic by 473.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares during the last quarter. Finally, Black Creek Investment Management Inc. grew its stake in shares of Hologic by 26.1% in the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock worth $262,453,000 after buying an additional 832,444 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on HOLX shares. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. BTIG Research restated a “neutral” rating on shares of Hologic in a report on Tuesday, October 21st. Evercore ISI downgraded Hologic from an “outperform” rating to an “in-line” rating and lowered their price target for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Finally, Morgan Stanley lifted their price target on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Three research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, Hologic has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Trading Down 0.1%

Shares of NASDAQ HOLX opened at $74.59 on Thursday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $75.36. The firm has a market cap of $16.65 billion, a PE ratio of 31.08, a price-to-earnings-growth ratio of 2.23 and a beta of 0.72. The business has a fifty day simple moving average of $74.88 and a two-hundred day simple moving average of $71.13. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business posted $0.87 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.